A SiftingSignal publication/ Edited by Simon Mathews, MD

The week in GI, filtered to what is worth knowing.

Every week, 200+ papers from 25+ top GI and medical journals, transparently scored and physician-vetted. The signal, not the noise.

This week, in numbers

Issue №18 · week of Nov 1, 2026See the trends →
Top journals this week: Lancet / Gastroenterology / Ann Intern Med / Hepatology
Selectivity
8.4%
22 in the issue of 262 screened
in the issue 22in depth 64held 14filtered out 162
91.6% of what published this week did not make the issue. That filter is the product. A further 64 cleared the bar and are carried in one line each, in full on the subspecialty pages.
How this week moves the standard
Changes practice 0
No paper this week forces an outright change to the standard. That is the usual, honest result.
Each paper is matched to the guideline that governs its question, then placed by how it moves it. 16 of the 22 cards in the issue are matched to a standard, and each of those quotes it with its source and review date. From issue 14, every match is independently re-checked, so this bar reads lower than in earlier issues. Click a segment to filter the issue.
The signal map
627283narrative reviewguideline →Clinical utilityEvidence strength
Each dot is a paper: evidence strength across, clinical utility up (what you can do with it, what rides on it, how many patients, how new), area = the journal's impact factor, colour = subspecialty. A dark ring marks a paper that refines or changes its standard of care. The vertical scale spans this week's cards and its numbers are the real scores out of 100. Click a dot to open its card.

What to know this week

the top-scored · the 5-minute version

timely therapy for acute severe AIH yields 79% 90-day transplant-free survival, AGA/AASLD 2026 PBC guideline: UDCA first, PPAR agonists for inadequate response, linerixibat for pruritus, and SC guselkumab induction matches IV efficacy in Crohn's disease, with 39.5-51.2% deep remission at Week 96.

The 22 in the issue this week, ranked by signal score. Each anchored to the relevant standard of care. All in full below; 64 more, read and scored the same way, in one line each at the foot of the issue.

Your subspecialty, the takeaways
IBD19Hepatology32Esophagus/Reflux4Pancreas/Biliary6Endoscopy9Motility6Colorectal6Nutrition4
Type

This week to know

the 9 strongest this week · each scored 0 to 100 on what it lets you do, who it touches, the stakes, and how well the evidence backs it
Hepatology meta analysis · n=2,456 · Oct 27, 2026 · Clin Gastro Hep · IF 16.2

Prevalence and outcomes of acute presentations of autoimmune hepatitis: Systematic Review and Meta-Analysis.

New evidenceautoimmune hepatitisacute liver failuresystematic reviewmeta-analysis
Clinical takeawayConsider acute presentations in nearly 40% of AIH patients, and prioritize timely therapy for acute severe AIH and acute/severe exacerbations, as these have favorable outcomes (79% TFS) compared to AIH-associated acute liver failure (19% TFS). Monitor AIH-associated acute liver failure closely due to poor transplant-free survival. Note that therapy should be tailored to disease severity and patient-specific factors, and adverse events should be monitored.
What it found39% of AIH patients present acutely, with 90-day transplant-free survival varying from 79% for acute severe AIH to 19% for AIH-associated acute liver failure.
ContextConfirms that acute presentations are common in AIH and highlights the heterogeneity in outcomes, refining understanding of clinical trajectories across subtypes. Applicable to adult patients with varying severity of AIH.
Emergingsuggested applicable standard· European Association for the Study of the Liver (EASL), 'EASL Clinical Practice Guidelines on the management of autoimmune hepatitis,' Journal of Hepatology, 2025 (vol. 83, no. 2, pp. 453-501)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

In adults with AIH, first-line induction is predniso(lo)ne of AT LEAST 0.5 mg/kg/day, potentially up to 1 mg/kg/day in more severe and advanced disease, in combination with EITHER azathioprine OR mycophenolate mofetil (LoE 2, strong recommendation; 82% agreement). Azathioprine is added only when bilirubin is <6 mg/dL and ideally 2 weeks after corticosteroid start (to avoid confusing non-response with azathioprine toxicity), at an initial dose of 50 mg/day titrated to a final dose of 1-2 mg/kg/day according to toxicity and response; azathioprine must never be used alone as induction; before starting azathioprine, thiopurine methyltransferase (TPMT) activity should ideally be tested to exclude COMPLETE (absent) TPMT activity, in which azathioprine is CONTRAINDICATED because of the risk of severe, potentially life-threatening myelosuppression, whereas in PARTIAL (intermediate/heterozygous) TPMT deficiency it may be used only with caution and dose reduction; azathioprine should likewise be given cautiously in pregnancy, cytopenias or malignancy, and should be AVOIDED in acute severe AIH and decompensated cirrhosis. Mycophenolate mofetil is dosed 1.5-2 g/day (0.75-1.0 g twice daily) and is positioned by EASL as an alternative first-line option to azathioprine; the CAMARO RCT found MMF superior to azathioprine in treatment-naive patients (CBR at 6 months 72.2% vs 32.3%, p=0.004) with fewer severe adverse events (0% vs 12.9%) and less withdrawal (5.1% vs 25.8%). MMF is teratogenic and counselling of both female and male patients is recommended (LoE 2, strong); it must be withdrawn at least 3 months before conception, and first presentations during pregnancy are treated with standard regimens EXCLUDING MMF. Induction therapy and corticosteroid tapering should be individualised according to CBR status (LoE 4, strong). Budesonide is NOT recommended as part of first-line treatment for AIH and is CONTRAINDICATED in patients with cirrhosis (LoE 2, strong; 82%), but it retains a defined second-line role: switching to budesonide may be suggested because of corticosteroid side effects in patients WITHOUT cirrhosis who are predniso(lo)ne-dependent (LoE 3, WEAK recommendation; 91%). Maintenance after CBR should consist of azathioprine or MMF as monotherapy OR in combination with low-dose corticosteroids (predniso(lo)ne ≤5 mg/day), with the dose adapted to sustain stable CBR (LoE 2, strong); low-dose predniso(lo)ne monotherapy can be suggested ONLY in patients with mild disease who achieved CBR and are intolerant to both azathioprine and MMF (LoE 3, weak). Most patients require long-term, often lifelong immunosuppression, and a trial of stopping is appropriate only in carefully selected patients whose low-dose monotherapy has maintained stable CBR for at least 2 years. For ACUTE SEVERE AIH the guideline stratifies by liver failure: in acute severe AIH WITHOUT ALF or ACLF, an early treatment trial with predniso(lo)ne 0.5-1 mg/kg/day (or intravenous methylprednisolone at equivalent dose) is recommended, and failure to improve after 3-7 days of treatment initiation should trigger REFERRAL TO A LIVER TRANSPLANT CENTRE (LoE 3, strong; 91%); in acute severe AIH WITH ALF or ACLF, direct evaluation (discussion with a transplant centre) for liver transplantation is recommended, because data on the role of corticosteroids in these patients is very limited and outcomes are poor (LoE 3, strong; 97%), and if corticosteroids are given, strict surveillance for infection and close monitoring of efficacy is recommended.

European Association for the Study of the Liver (EASL), 'EASL Clinical Practice Guidelines on the management of autoimmune hepatitis,' Journal of Hepatology, 2025 (vol. 83, no. 2, pp. 453-501) · reviewed 2026-07-23 ↗
Taneja S … Duseja A · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatology guideline · Nov 1, 2026 · Gastroenterology · IF 25.1

AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis.

Guideline / reviewPBCguideline
Clinical takeawaySix recommendations: PBC-specific antinuclear antibodies in AMA-negative suspected PBC, UDCA first line, liver stiffness for prognosis, PPAR agonists for inadequate response or intolerance to UDCA, linerixibat for moderate to severe pruritus, and UDCA after transplant to reduce recurrence. Certainty of evidence was moderate to very low.
What it foundThe guideline provides 6 recommendations, including UDCA as first-line therapy, liver stiffness measurement for prognostication, and linerixibat for moderate to severe pruritus, compared to older therapies like rifampin and naltrexone.
ContextThis guideline refines current practice by providing evidence-based recommendations for diagnosis, treatment escalation, symptom management, and post-transplantation care in adults with PBC.
Measured against the standard of care· AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance

Decision at stakethe use of UDCA as first-line therapy for PBC

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. … If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. … After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Adults with PBC: ursodeoxycholic acid (UDCA) is first-line for every patient, started at diagnosis (a strong recommendation); the 13-15 mg/kg/d dose comes from the 2018/2021 AASLD guidance, which the 2026 guideline adds to rather than replaces. If antimitochondrial antibodies (AMA) are negative and PBC is suspected, test for the PBC-specific antinuclear antibodies SP100 and GP210, which may avoid a liver biopsy. Measure liver stiffness (elastography) to estimate the risk of progression; the guideline says the best interval for repeat elastography is unknown. If the response to UDCA is inadequate, consider adding a PPAR agonist; if UDCA is not tolerated, consider a PPAR agonist instead. The patient summary names seladelpar and elafibranor, which have FDA accelerated approval as second-line drugs and are not recommended in decompensated cirrhosis. Off-label fibrates (bezafibrate, fenofibrate) are discouraged in decompensated cirrhosis. Obeticholic acid is no longer a US option: it was withdrawn from the market in late 2025, and the 2026 guideline makes no recommendation on it. For moderate-to-severe cholestatic pruritus, consider the IBAT inhibitor linerixibat through shared decision-making that weighs its GI side effects (diarrhea, abdominal pain), cost and patient preference; the older bile-acid sequestrant, rifampin, naltrexone and sertraline ladder from the 2021 guidance still applies. After liver transplant for PBC, give UDCA prophylaxis to reduce recurrence and graft failure. Certainty of evidence ranges from moderate to very low. The guideline found too little evidence to recommend anything for patients who do not respond to second-line therapy, and the long-term effect of PPAR agonists on mortality, transplant-free survival and decompensation is not established.

AGA/AASLD 2026 Clinical Practice Guideline (Gastroenterology 2026;171(5):817-839; Hepatology 2026), complementing AASLD 2018/2021 Practice Guidance · reviewed 2026-10-25 ↗
Levy C … Davitkov P · Gastroenterology · IF 25.1 · PubMed ↗Permalink
IBD rct · n=600 · Oct 27, 2026 · Clin Gastro Hep · IF 16.2

Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI.

New evidenceCrohn's diseasebiologicstherapeutic drug monitoring
Clinical takeawayConsider SC guselkumab induction as an equally effective alternative to IV induction for moderately to severely active Crohn's disease, given similar efficacy and safety profiles, with adverse events comparable to placebo.
What it foundIV and SC guselkumab induction were equally effective for moderately to severely active Crohn's disease, with 39.5-51.2% achieving deep remission at Week 96 compared to placebo.
ContextConfirms that SC induction is non-inferior to IV induction for guselkumab in moderately to severely active Crohn's disease, aligning with current practice favoring SC administration for convenience.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
D'Haens GR … Sands BE · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBD meta analysis · Nov 1, 2026 · Inflamm Bowel Dis · IF 4.5

Biologics and small molecules for perianal Crohn's disease: a systematic review and meta-analyses of randomized placebo-controlled trials.

New evidenceCrohn's diseasebiologicsJAK inhibitorsperianal disease
Clinical takeawayEvidence is strongest for infliximab; data for adalimumab, ustekinumab and upadacitinib are limited and mostly post hoc analyses of luminal trials with moderate to serious risk of bias.
What it foundAcross 14 placebo-controlled studies (only 4 designed for perianal disease), advanced therapies improved induction fistula response (RR 1.65) and remission (RR 1.91), and maintenance response (RR 1.54) and remission (RR 2.08). Infliximab and upadacitinib improved response and remission in induction, and infliximab also in maintenance.
ContextNo head-to-head or line-of-therapy comparisons were made.
Measured against the standard of care· ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH)

… MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. … Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text. The rest of this standard includes DIAGNOSIS.

Our full summary of this standard

Two current US guidelines govern Crohn's disease and should be read together. ACG 2025 (Lichtenstein et al.) remains the reference for diagnosis, mild-to-moderate disease, perianal, postoperative and abscess management. DIAGNOSIS: fecal calprotectin (>50-100 μg/g) separates inflammatory from noninflammatory disease of the colon. Workup is ileocolonoscopy with biopsies, including uninvolved mucosa, plus small-bowel imaging. CTE and MRE are comparable; prefer MRE in patients <35 y and when serial exams are likely. Intestinal ultrasound is an ungraded adjunct. Do routine CRC surveillance in Crohn's colitis. MILD-TO-MODERATE: recommend against oral mesalamine; sulfasalazine only for symptomatic mild colonic CD; ileal-release budesonide 9 mg for induction in ileocecal disease but not for maintenance. MODERATE-TO-SEVERE (AGA Living Guideline, Scott et al., Gastroenterology 2025;169(7):1397-1448, 16 recommendations: 1 strong, 9 conditional, 6 knowledge gaps; updated quarterly, adult outpatients only): RECOMMEND infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab or upadacitinib over no treatment; SUGGEST certolizumab pegol or vedolizumab over no treatment. Advanced-therapy-naive: suggest higher-efficacy agents (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) over lower-efficacy ones (certolizumab pegol, upadacitinib). Prior advanced-therapy (especially anti-TNF) exposure: suggest higher- or intermediate-efficacy agents (adalimumab, risankizumab, guselkumab, upadacitinib; ustekinumab, mirikizumab) over lower-efficacy ones (vedolizumab, certolizumab pegol). Suggest against thiopurine monotherapy for induction; suggest it for maintenance of remission. Suggest SC/IM methotrexate monotherapy; suggest against oral methotrexate. In thiopurine-naive patients starting infliximab, suggest infliximab + thiopurine over infliximab alone. No recommendation on IFX + MTX, adalimumab + immunomodulator, or non-TNF biologic + immunomodulator. After ≥6 months of steroid-free remission on anti-TNF + immunomodulator, suggest withdrawing the immunomodulator and suggest against withdrawing the anti-TNF. SUGGEST upfront advanced therapy over step-up therapy (corticosteroids and/or immunomodulator first). No recommendation on treating to endoscopic vs symptomatic remission. The ACG 2025 moderate-to-severe recommendations (anti-TNF, IFX + thiopurine combination and IL-12/23/IL-23 agents, each strong/moderate; upadacitinib after anti-TNF exposure; steroids for short-term induction only; TPMT/NUDT15 testing before thiopurines) still stand alongside AGA. ACG perianal (infliximab first; drain abscesses and place setons before escalating), postoperative (endoscopy at 6-12 months; anti-TNF strong, vedolizumab conditional in high-risk patients) and intra-abdominal abscess (>2 cm: antibiotics plus drainage, hold immunosuppression) positions are unchanged. THERAPEUTIC ENDOSCOPY (AGA Clinical Practice Update, CGH 2026; details below come from AGA news coverage, not the full text, and are ungraded advice): get cross-sectional imaging before the procedure. Endoscopic balloon dilation is first-line for short strictures (about ≤4-5 cm) with few risk factors (fistula, prestenotic dilation >5 cm, high CRP, prior anti-TNF). Longer or multiple strictures, or ≥3 risk factors, favor surgery.

ACG 2025 (Lichtenstein et al., Am J Gastroenterol) / AGA Living Guideline 2025 (Scott et al., Gastroenterology) / AGA Clinical Practice Update on Therapeutic Endoscopy in IBD 2026 (CGH) · reviewed 2026-10-11 ↗
Yuan Y … Vuyyuru SK · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
Colorectal meta analysis · n=761 · Oct 27, 2026 · Ann Intern Med · IF 19.6

Laparoscopic Versus Open Liver Resection for Colorectal Liver Metastases : An Individual Participant Data Meta-analysis of Four Randomized Clinical Trials.

New evidencecolorectal surgerymeta-analysissystematic reviewhealth services
What it foundLaparoscopic liver resection for colorectal metastases reduced postoperative morbidity to 19% versus 27% for open resection, with no difference in overall or disease-free survival at a median 93-month follow-up. However, 90-day mortality was higher in the laparoscopic group (1.8%) compared to the open group (0.8%).
ContextThis literature reports that laparoscopic liver resection (LLR) and open liver resection (OLR) for colorectal liver metastases (CRLM) are compared in terms of postoperative and long-term oncologic outcomes, with ongoing evaluation of subgroup effects.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Olij B … LLR vs OLR IPDMA Collaborators · Annals of Internal Medicine · IF 19.6 · PubMed ↗Permalink
IBD rct · n=106 · Oct 28, 2026 · Clin Gastro Hep · IF 16.2

Endoscopic Balloon Dilation Versus Endoscopic Stricturotomy for Short Crohn's Disease Strictures: The BEST-CD Randomized Trial.

New evidenceCrohn's diseaseIBD surgery
Clinical takeawayConsider endoscopic stricturotomy (ES) over endoscopic balloon dilation (EBD) for short (<3 cm) Crohn's disease strictures in expert centers, as ES reduces recurrence and reintervention rates. Adverse events were similar between groups (13.2% vs 22.6%; p=0.30).
What it foundEndoscopic stricturotomy (ES) reduced 1-year clinical recurrence to 30.1% compared to 54.7% with endoscopic balloon dilation (EBD) in short Crohn's disease strictures.
ContextChallenges the current standard of EBD for short Crohn's strictures, showing ES offers superior outcomes in recurrence and reintervention rates compared to EBD.
Refinessuggested applicable standard· British Society of Gastroenterology, 'UK guidelines on oesophageal dilatation in clinical practice' (Sami SS et al., Gut 2018;67(6):1000-1023). DOI 10.1136/gutjnl-2017-315414, PMID 29478034. Achalasia-specific dilation is governed by ASGE, 'ASGE guideline on the management of achalasia' (Khashab MA et al., Gastrointest Endosc 2020;91(2):213-227.e6, DOI 10.1016/j.gie.2019.04.231, PMID 31839408).

Widen symptomatic GI luminal strictures with mechanical bougie (Savary-Gilliard) or through-the-scope hydrostatic balloon dilation. … Treat the underlying condition first, topical steroid optimization for EoE strictures and biologic optimization for inflammatory Crohn's strictures, before or alongside dilation. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Widen symptomatic GI luminal strictures with mechanical bougie (Savary-Gilliard) or through-the-scope hydrostatic balloon dilation. For achalasia, use a pneumatic balloon (Rigiflex, starting at 30 mm) with graded dilation over multiple sessions to minimize perforation risk, and always biopsy to rule out malignancy at the index procedure. For non-achalasia strictures, keep the two techniques distinct rather than applying one rule to both. The 'rule of 3' is a BOUGIE (wire-guided push-dilator) rule and its trigger is tactile: once moderate resistance is felt, pass no more than 3 progressively larger dilators in roughly 1 mm (3-Fr) steps in that session. A balloon transmits no such resistance, so the rule does not transfer to it. Balloon (TTS/hydrostatic) dilation is governed instead by matching the balloon to the stricture and dilating to a pre-selected target diameter under direct endoscopic vision, with fluoroscopy added for tortuous, long or high-risk strictures; limit the first session to 10-12 mm when the stricture will not admit an adult gastroscope (9 mm or less if filiform) and repeat sessions weekly to fortnightly until easy passage of a 15 mm or larger dilator is achieved along with symptomatic improvement. BSG 2018 does advise using no more than three successively larger diameter increments in a single session for BOTH bougie and balloon dilators, but grades that advice low quality / low strength and states explicitly that the precise 3x1 mm restriction is not evidence based, 2x1 mm may be safer in very tight or long strictures and 4x1 mm or 3x2 mm may be used safely in looser strictures or ones that have completely recurred. Treat it as a ceiling to be justified, not as a technique-independent law, and do not carry the bougie resistance trigger over to balloon dilation. Treat the underlying condition first, topical steroid optimization for EoE strictures and biologic optimization for inflammatory Crohn's strictures, before or alongside dilation. For refractory benign strictures, inject intralesional triamcinolone (40 mg in 4 quadrants) and escalate to POEM/surgery or SEMS for malignant strictures as indicated.

British Society of Gastroenterology, 'UK guidelines on oesophageal dilatation in clinical practice' (Sami SS et al., Gut 2018;67(6):1000-1023). DOI 10.1136/gutjnl-2017-315414, PMID 29478034. Achalasia-specific dilation is governed by ASGE, 'ASGE guideline on the management of achalasia' (Khashab MA et al., Gastrointest Endosc 2020;91(2):213-227.e6, DOI 10.1016/j.gie.2019.04.231, PMID 31839408). · reviewed 2026-07-21 ↗
Pal P … Reddy DN · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
IBD meta analysis · n=2,142 · Oct 27, 2026 · Eur J Gastro Hep · IF 2.2

Efficacy and safety of guselkumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.

New therapybiologicssystematic reviewmeta-analysis
Clinical takeawayConsider guselkumab as a treatment option for patients with moderate-to-severe ulcerative colitis or Crohn's disease, particularly those who have failed or are intolerant to other therapies, given its favorable safety profile.
What it foundGuselkumab tripled week-12 clinical remission rates (risk ratio: 2.77, 95% CI: 2.30-3.34) and halved serious adverse events (risk ratio: 0.57) versus placebo in moderate-to-severe IBD.
ContextThis meta-analysis confirms guselkumab's efficacy and safety in IBD, adding to the growing evidence for IL-23 inhibitors as a therapeutic class.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. … Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. … Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Shahid ZUA … Razzak MJ · European Journal of Gastroenterology & Hepatology · IF 2.2 · PubMed ↗Permalink
Hepatology prospective cohort · n=159,572 · Nov 1, 2026 · Liver International · IF 6.7

The aMAP Score Effectively Stratifies Hepatocellular Carcinoma Risk in the Steatotic Liver Disease Population.

New evidencehepatocellular carcinomaMASLDbiomarkerepidemiology
Clinical takeawayIn steatotic liver disease, an aMAP above 64 marked a very-high-risk group (15-year HCC incidence 3.1% to 5.4%) that the authors judge reaches the surveillance threshold; the refined cutoff was derived and validated within the UK Biobank.
What it foundThe aMAP score stratified HCC risk in SLD patients, with a 15-year cumulative incidence of 1.43% in the high-risk group vs. 0.06% in the low-risk group (HR 28.51, 95% CI 19.58-41.52), and a refined cutoff (aMAP > 64) identified a very-high-risk subgroup.
ContextaMAP, developed mainly in viral hepatitis, discriminated HCC risk in steatotic liver disease (C-index 0.80 in UK Biobank, 0.79 in a Chinese cohort) and was compared with PAGE-B, mPAGE-B, CAMD and MASLD-HCC.
Measured against the standard of care· AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Perform HCC surveillance with abdominal ultrasound PLUS serum AFP every ~6 months (semiannual, not annual) in adults with cirrhosis of any etiology who could benefit from HCC treatment: Child-Turcotte-Pugh A or B, and CTP C only if a liver-transplant candidate or listed. Do not surveil patients whose life expectancy is <1-2 years from comorbidity that neither transplantation nor HCC therapy can remedy, and weigh the physical, psychological and financial harms of surveillance case by case. Also surveil selected non-cirrhotic chronic HBV carriers: Asian men >40 and women >50 from endemic regions, people of African origin at younger ages, family history of HCC, or high viral load/active hepatitis. AGA 2026 endorses PAGE-B (intermediate/high risk at ≥10) and REAL-B to stratify these patients. Patients with HCV cirrhosis stay in surveillance after SVR. Patients without cirrhosis from other causes are NOT surveilled because incidence is too low (≤F3 fibrosis, MASLD without cirrhosis, HCV cured before cirrhosis), though fibrosis staging uncertainty warrants individual discussion. CT/MRI are not routine surveillance tools. Abbreviated MRI, GALAD and other blood biomarkers are investigational and should not replace ultrasound+AFP until trials such as TRACER and PREMIUM report. Multicancer blood detection tests should not be used. AGA 2026 states that preventing cirrhosis (treating viral hepatitis, metabolic disease and alcohol use disorder) is the most effective way to reduce HCC deaths. Recall per AASLD 2023: AFP ≥20 ng/mL or a rising AFP (doubling, or a rise on two consecutive tests even below 20), any ultrasound observation ≥1 cm, or an inadequate ultrasound triggers multiphasic contrast CT or MRI read with LI-RADS. Treatment per AASLD 2023 is BCLC-linked: resection, ablation or transplant within Milan criteria for very-early/early disease, TACE and other locoregional therapy for intermediate disease, systemic therapy for advanced disease. Preferred first-line systemic therapy in Child-Pugh A is atezolizumab+bevacizumab or durvalumab+tremelimumab (STRIDE); sorafenib, lenvatinib or durvalumab monotherapy are the alternatives. BEACON-HCC (AASLD/HCC-LIVE, Hepatology, online August 2026) is a modified-Delphi North American consensus framework for treatment allocation. It weighs tumor burden, vascular invasion, tumor biology, liver function and local-therapy availability, and it complements BCLC without replacing it. In its 29-case pilot it matched multidisciplinary decisions 96.6% of the time and BCLC 2025 72.4% of the time. Under BEACON-HCC, macrovascular invasion does not automatically mean systemic therapy, and EBRT/SBRT and TARE are primary options. Continue post-treatment surveillance with contrast-enhanced cross-sectional imaging early after curative therapy.

AASLD 2023 Practice Guidance (Hepatology 78(6):1922-1965) / AGA Clinical Practice Update 2026 (Rich et al., Gastroenterology, doi 10.1053/j.gastro.2026.03.006) / BEACON-HCC consensus 2026 (Hepatology, doi 10.1097/hep.0000000000001834) · reviewed 2026-10-25 ↗
Xu W … Chronic Hepatitis B Study Consortium · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Endoscopy rct · n=266 · Oct 28, 2026 · Clin Gastro Hep · IF 16.2

Real-time Voice-Guided Artificial Intelligence Improves Biliopancreatic Endosonography Quality: A Randomized Trial.

New evidenceartificial intelligenceEUSendoscopy qualitycomputer-aided detection
Clinical takeawayConsider using AI-assisted EUS (EUS-GUIDEQ) to improve adherence to guideline-recommended biliopancreatic scanning stations, particularly in settings where completeness is a priority, while accounting for the modest increase in procedure time.
What it foundAI-assisted EUS (EUS-GUIDEQ) improved station completeness to 1.00 (IQR 0.94-1.00) vs 0.81 (IQR 0.75-0.88) with standard EUS (P<0.001), but increased procedure time by 2.15 minutes. No serious procedure-related adverse events occurred.
ContextConfirms the potential of AI to enhance procedural quality in EUS, addressing known variability in operator adherence to guideline-recommended scanning protocols in adult patients undergoing biliopancreatic EUS.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Wang R … Wang X · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink

The read

the next 13, in full

IBD· 1

IBD meta analysis · n=2,245 · Oct 27, 2026 · Eur J Gastro Hep · IF 2.2

Differential efficacy of interleukin-23 pathway inhibitors in ulcerative colitis according to disease extent: a systematic review and meta-analysis of randomized trials.

New evidenceulcerative colitisbiologicssystematic reviewmeta-analysis
Clinical takeawayConsider IL-23 pathway inhibitors for moderate-to-severe ulcerative colitis regardless of disease extent, but anticipate a stronger maintenance effect in extensive disease.
What it foundIL-23 inhibitors increased clinical remission compared to placebo in limited disease (RR 2.58, 95% CI 1.94-3.43) and extensive disease (RR 2.25, 95% CI 1.62-3.13) during induction, with a greater relative effect in extensive disease during maintenance (RRR 2.16, 95% CI 1.47-3.19, P < 0.001).
ContextConfirms efficacy of IL-23 inhibitors in moderate-to-severe ulcerative colitis and refines understanding of their differential maintenance effect by disease extent.
Measured against the standard of care· AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026)

Decision at stakepositioning advanced therapy by efficacy tier in moderate-to-severe UC

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. … Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Outpatient positioning is unchanged from the ACG 2025 UC guideline and the AGA living guideline for moderate-to-severe UC. Confirm UC with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step C. difficile testing. Treat mild-moderate disease with 5-ASA chosen by route and extent: suppository for proctitis, enema for left-sided disease, oral plus rectal for extensive disease. If 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by efficacy tier, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab. Intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab. Lower: adalimumab. Previously TNF-exposed, higher efficacy: tofacitinib, upadacitinib, ustekinumab. Lower: adalimumab, vedolizumab, ozanimod, etrasimod. After anti-TNF primary non-response, switch mechanism rather than cycling within the class. Treat to target (STRIDE-II): endoscopic improvement, Mayo endoscopic subscore 0-1. Begin CRC surveillance 8-10 years after diagnosis for extensive or left-sided disease; isolated proctitis follows average-risk screening. Inpatient care now follows the 2026 AGA Clinical Practice Update (13 best-practice statements). Admit for severe symptoms refractory to outpatient therapy, suspected complications (obstruction, abscess, toxic megacolon) or significant malnutrition, and identify acute severe UC by Truelove-Witts. Give every patient admitted with diarrhea two-step C. difficile testing. Test for CMV, with early endoscopy, if symptoms worsen, the patient is systemically toxic or disease is steroid-refractory. Give routine VTE prophylaxis with LMWH or fondaparinux unless contraindicated, and individualize post-discharge extension. Give IV methylprednisolone 60 mg/day or equivalent; the AGA living guideline says 40-60 mg/day, and higher doses add no benefit. Do not give adjunctive antibiotics without infection. Involve surgery early. Assess response by day 3 (72 h) using stool frequency and CRP (Oxford criteria); do not continue IV steroids beyond about 7 days without response. Rescue steroid non-responders with infliximab (accelerated or intensified dosing in selected patients with high inflammatory burden or protein-losing colopathy), cyclosporine, or a JAK inhibitor at standard or intensified dosing, or with colectomy. Before discharge, the response should be stable and a transition plan should be in place.

AGA Clinical Practice Update on Inpatient Management of Adults With IBD (Gastroenterology 2026) / ACG UC Guideline Update 2025 / AGA Living Guideline, Moderate-to-Severe UC 2024 (panel review March 2026) · reviewed 2026-10-11 ↗
Kaur A … Goren I · European Journal of Gastroenterology & Hepatology · IF 2.2 · PubMed ↗Permalink

Hepatology· 6

Hepatology prospective cohort · n=1,590 · Oct 31, 2026 · Lancet · IF 98.4

Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study.

DiagnosticbiomarkerMASLDepidemiology
Clinical takeawayConsider using SomaSignal as a non-invasive biomarker for detecting at-risk MASH, advanced fibrosis, and cirrhosis in MASLD patients, potentially reducing the need for liver biopsy, but further validation in diverse populations is needed.
What it foundSomaSignal achieved AUC 0.83 for at-risk MASH, AUC 0.92 for advanced fibrosis, and AUC 0.92 for cirrhosis, exceeding the minimum acceptable criterion (AUC >0.80) for biopsy replacement, compared to other non-invasive biomarkers.
ContextThis study provides robust evidence supporting the use of non-invasive biomarkers in MASLD, refining the diagnostic approach and potentially replacing biopsy in certain cases, though limitations and adverse events were not reported.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

Decision at stakethe use of non-invasive tests to identify patients with at-risk MASH and advanced fibrosis

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. … Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Vali Y … LITMUS Investigators · The Lancet · IF 98.4 · PubMed ↗Permalink
Hepatology prospective cohort · n=162,456 · Oct 27, 2026 · Clin Gastro Hep · IF 16.2

High burden of potentially undiagnosed MASH in a general population in Sweden.

DiagnosticepidemiologyMASLDbiomarkerhealth services
Clinical takeawayIn routine Stockholm care data, high-risk FNI with a cardiometabolic risk factor carried 4.6-fold the MALO rate of low FNI; whether acting on FNI changes outcomes was not tested.
What it foundHigh-risk FNI patients (FNI≥0.33 and ≥1 cardiometabolic risk factor) had a 4.6-fold higher risk of major adverse liver outcomes (MALO) compared to low-risk FNI patients (FNI<0.1).
ContextThis study highlights the utility of FNI in identifying undiagnosed MASH patients at high risk of adverse outcomes, reinforcing the need for earlier diagnosis and intervention in this population.
Measured against the standard of care· EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

This standard applies to MASLD: hepatic steatosis on imaging or biopsy, at least one cardiometabolic criterion, no other liver disease, and alcohol below the MetALD range. The AGA 2026 MetALD update sets MetALD at about 140-350 g/week of alcohol in women and 210-420 g/week in men, averaged over at least 3 months. MASLD therefore means under about 140 g/week (women) or 210 g/week (men), and drinking above the MetALD range is ALD. Assess alcohol use in every patient with steatotic liver disease at diagnosis and at least once a year, by interview, a validated questionnaire (e.g., AUDIT-C) and/or biomarkers such as phosphatidylethanol (PEth). Advise every patient with steatotic liver disease to stop drinking. Screen people with type 2 diabetes, people with overweight or obesity plus at least one more metabolic risk factor, and anyone with incidental steatosis or raised aminotransferases. Use FIB-4 first. A score below 1.3 (below 2.0 at age 65 or older) is low risk: the patient stays in primary care and repeats FIB-4 every 1-2 years. A score at or above the cutoff goes to a second-line test: VCTE, or ELF if elastography is not available. VCTE below 8 kPa is low risk. VCTE of 8 kPa or more, or ELF of 9.2 or more, means clinically significant fibrosis is likely and the patient should be referred to hepatology. Read liver stiffness with caution if the patient is actively drinking. Reserve biopsy for discordant or unclear results. Lifestyle change is the base of treatment for everyone: at least 5% weight loss improves steatosis, and 10% or more is usually needed for fibrosis to improve. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and F2-F3 fibrosis (by non-invasive tests or biopsy), alongside structured lifestyle intervention and optimised management of comorbidities. The NIT ranges that stand in for F2-F3 differ by society. AASLD uses VCTE 8-15 kPa, MRE 3.1-4.4 kPa or ELF 9.2-10.5. EASL-EASD-EASO 2026 frames the treatable high-risk group as, for example, VCTE 10-20 kPa, MRE 3.1-5.0 kPa or ELF 9.8-11.3. Two drugs are approved: resmetirom (80 mg oral daily, or 100 mg at body weight of 100 kg or more; AASLD Oct 2024 guidance) and semaglutide 2.4 mg subcutaneously once weekly (FDA accelerated approval Aug 2025, AASLD Nov 2025 guidance; in ESSENCE, MASH resolved without fibrosis worsening in 62.9% vs 34.3% on placebo). EASL-EASD-EASO 2026 says to choose between them by patient preference, risks and cardio-renal-metabolic profile. Semaglutide may be preferred with obesity, type 2 diabetes, established cardiovascular disease or high cardiovascular risk. Resmetirom may be prioritised without obesity, or when the patient is already on or cannot tolerate a GLP-1 receptor agonist. On semaglutide, monitoring includes nutrition and sarcopenia assessment, and fibrosis NITs are used over time to judge response. In MASH cirrhosis, resmetirom and semaglutide appear safe but should not be used as MASH-targeted treatment until liver-related benefit is shown. Pioglitazone or vitamin E remain options under the AASLD 2023 guidance. Neither resmetirom nor semaglutide has been formally studied in MetALD. Manage cardiometabolic risk in every patient whatever the fibrosis stage, including statins for ASCVD and control of glucose and blood pressure. On semaglutide, watch for GI side effects and rare risks (AKI, gallbladder disease, pancreatitis, retinopathy, loss of lean mass). For MetALD, treat moderate or severe alcohol use disorder with medication plus behavioural therapy, correct micronutrient deficiencies (folate, thiamine, vitamin D), and do not offer bariatric or endobariatric procedures. HCC surveillance with ultrasound, with or without AFP, every 6 months is indicated only when cirrhosis is present.

EASL-EASD-EASO 2026 Guidance on Resmetirom and Semaglutide as MASH-Targeted Therapy (J Hepatol, doi:10.1016/j.jhep.2026.08.028) / AASLD 2023 Practice Guidance (+ Oct 2024 resmetirom and Nov 2025 semaglutide updates) / AGA 2026 Clinical Care Pathway for MASLD (Gastroenterology, doi:10.1053/j.gastro.2026.01.047) / AGA 2026 Clinical Practice Update on MetALD (Clin Gastroenterol Hepatol, 2026) / EASL 2026 SLD trajectory guidance (JHEP Rep, doi:10.1016/j.jhepr.2026.101798) · reviewed 2026-10-11 ↗
Grip ET … Hagström H · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
Hepatology rct · n=50 · Nov 1, 2026 · Liver International · IF 6.7

Effects of Aerobic Exercise on Autonomic and Endothelial Function and Splanchnic Hemodynamics in Compensated Cirrhosis: RCT Study.

New evidencecirrhosisportal hypertension
Clinical takeawayConsider recommending a 16-week moderate-intensity aerobic exercise program (e.g., brisk walking) to improve functional capacity and portal vein hemodynamics in patients with compensated cirrhosis, while acknowledging the lack of between-group significance in autonomic and hepatic parameters.
What it foundAerobic exercise improved 6-minute walk test distance by 32 meters (IQR: 12.00-51.60 m, p < 0.01) compared to nutritional consultation alone and increased portal vein volume flow by 350.66 mL/min (p = 0.003) in compensated cirrhosis, though positive signals in autonomic and hepatic parameters were not between-group significant.
ContextThis RCT provides evidence that aerobic exercise is safe and beneficial in compensated cirrhosis, refining prior observational data on exercise in liver disease.
Measured against the standard of care· ACG 2026 (Tapper EB et al., ACG Clinical Guideline: Preventive Care for Patients With Cirrhosis, Am J Gastroenterol, online 2026-10-05)

… Carvedilol is also suggested in compensated cirrhosis with clinically significant portal hypertension to prevent a first episode of ascites; CSPH can be estimated noninvasively from transient elastography plus platelet count. … Structured aerobic and resistance exercise for ambulatory patients. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

ACG 2026 (Tapper et al., Am J Gastroenterol, online 2026-10-05) gives 18 GRADE recommendations and 6 key concepts on preventive care in cirrhosis; most of the evidence is low certainty. Varices: carvedilol (12.5 mg daily, with no titration to a heart-rate target) or endoscopic variceal ligation as primary prophylaxis for high-risk esophageal varices. This is strong, and it is the only moderate-certainty recommendation. Carvedilol is also suggested in compensated cirrhosis with clinically significant portal hypertension to prevent a first episode of ascites; CSPH can be estimated noninvasively from transient elastography plus platelet count. HCC: ultrasound plus AFP every 6 months for patients who are candidates for HCC treatment (strong). Aspirin is not recommended for HCC prevention, and statins should not be started only for chemoprevention without a conventional cardiovascular indication. Vaccination: test hepatitis A immunity and vaccinate if not immune; annual influenza; a SARS-CoV-2 series; RSV (bivalent vaccine) at age 50 or older; all strong. Test hepatitis B immunity and vaccinate (conditional), and revaccinate non-responders, considering the TLR9-adjuvanted vaccine. Hepatic encephalopathy: lactulose over no treatment for minimal HE; no rifaximin for primary prevention in minimal HE; add rifaximin if overt HE develops on lactulose. Upper GI bleeding, variceal or not: a 2-3 day course of prophylactic antibiotics. Albumin 6-8 g per liter removed for paracentesis over 5 L. Nutrition: dietitian-guided, protein 1.2-1.5 g/kg ideal body weight per day and 30-35 kcal/kg per day, lower in obesity. Structured aerobic and resistance exercise for ambulatory patients. Bisphosphonates for osteoporosis; varices alone do not rule out oral bisphosphonates. Screen for alcohol use disorder at every visit, treat with naltrexone or acamprosate, and offer behavioral therapy after discharge to hospitalized patients with AUD. Smoking-cessation counseling (strong). Clinic follow-up within 14 days of discharge. Consider age-appropriate cancer screening for transplant candidates and for non-frail compensated patients without life-limiting comorbidity.

ACG 2026 (Tapper EB et al., ACG Clinical Guideline: Preventive Care for Patients With Cirrhosis, Am J Gastroenterol, online 2026-10-05) · reviewed 2026-10-11 ↗
Kittiprachakul S … Chaiteerakij R · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatology retrospective · n=1,234 · Nov 1, 2026 · Liver International · IF 6.7

Trends in Hepatitis D Virus Prevalence Among HBsAg-Positive Individuals With and Without HIV in Italy: A Converging Epidemiology.

New evidenceepidemiologyviral hepatitis
Clinical takeawayConsider HDV screening in HBsAg-positive individuals, as HIV status no longer identifies a higher-risk subgroup.
What it foundAnti-HDV prevalence among HBsAg-positive PWH declined from 19.1% to 12.5%, converging with HIV-negative individuals (12.7%), and HIV status was no longer independently associated with HDV infection.
ContextChallenges prior practice of targeting HDV screening primarily in PWH, supporting broader screening in HBsAg-positive individuals.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Puoti M … PITER, MASTER and ICONA Study Groups · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatology meta analysis · n=5,045 · Nov 1, 2026 · Liver International · IF 6.7

Network Meta-Analysis: Treatments for Acute Alcohol-Associated Hepatitis.

New evidencealcohol-associated liver diseasemeta-analysissystematic reviewbiomarker
Clinical takeawayNot a basis for routine use: the effect disappeared when only low-risk-of-bias studies were analysed, and the authors call for adequately powered trials.
What it foundGranulocyte colony stimulating factor (GCSF) reduced 90-day mortality risk by 51% (RR 0.49, 95% CI 0.28-0.84) compared to placebo in acute alcohol-associated hepatitis, though subgroup analysis of low-risk-of-bias studies showed no significant effect.
ContextChallenges current practice: no treatment has shown consistent survival benefit in AH, and GCSF emerges as a promising candidate, though further high-quality trials are needed.
Emergingsuggested applicable standard· American College of Gastroenterology (ACG), "ACG Clinical Guideline: Alcohol-Associated Liver Disease" (Jophlin, Singal, Bataller, et al.), Am J Gastroenterol 2024;119(1):30-54

… For alcohol-associated hepatitis (AH), severity is stratified by MELD: MELD >20 defines severe AH, which carries high short-term mortality and should preferably be managed in hospital; MELD ≤20 defines moderate AH. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Treatment of AUD with sustained abstinence is the most effective strategy to prevent progression and improve long-term outcomes at any stage of ALD; ACG recommends brief screening with a tool such as AUDIT-C (strong, high), brief motivational interventions (strong, low), and integrated multidisciplinary care combining behavioral therapy and/or pharmacotherapy (strong, low). AUD pharmacotherapy recommendations are scoped specifically to COMPENSATED ALD and are not co-equal: baclofen is recommended as an option (strong recommendation, moderate evidence); acamprosate or naltrexone are only suggested as options (conditional, very low); gabapentin or topiramate are suggested as options (conditional, very low); disulfiram is suggested AGAINST along any spectrum of ALD (conditional, very low). For severe alcohol withdrawal, benzodiazepines are the treatment of choice but with explicitly cautious use and careful monitoring given their potential to precipitate or exacerbate hepatic encephalopathy (strong, moderate); AWS is managed per CIWA-Ar protocol, differentiating it from HE while acknowledging the two can coexist. For alcohol-associated hepatitis (AH), severity is stratified by MELD: MELD >20 defines severe AH, which carries high short-term mortality and should preferably be managed in hospital; MELD ≤20 defines moderate AH. In severe AH (MELD >20) ACG recommends corticosteroid therapy ONLY if there are no contraindications (strong, moderate); active infection (including untreated HBV infection), uncontrolled diabetes mellitus, gastrointestinal bleeding, and severe renal failure are contraindications to corticosteroid use, though corticosteroids can be started after adequate control or reversal of infection, renal failure, and gastrointestinal bleeding. Prednisolone is preferred over prednisone; both are dosed 40 mg/day for a total of 4 weeks, with IV methylprednisolone 32 mg/day as the alternative for patients unable to take oral medication; there is no evidence supporting rapid vs slow tapering after the 4-week course. Corticosteroid response is assessed by Lille score at day 7 OR day 4 (day-4 shown as accurate as day-7); among non-responders (Lille >0.45) corticosteroids should be discontinued. ACG recommends IV N-acetylcysteine as an adjuvant to corticosteroids in severe AH (strong, moderate), while explicitly noting that other society guidelines have not adopted this recommendation. ACG recommends AGAINST pentoxifylline (strong, moderate) and AGAINST universal prophylactic antibiotics in hospitalized severe AH (strong, moderate); data on G-CSF and microbiome-based therapies are insufficient. Nutrition: target 35 kcal/kg/day with 1.2-1.5 g/kg/day protein; patients consuming <21 kcal/kg/day should receive nutritional support, preferably oral/enteral, oral nutritional supplements first, escalating to enteral nutrition if caloric targets remain unmet (strong, moderate). Thiamine, vitamin B12 and zinc deficiencies are common in AH and should be supplemented. For severe AH unresponsive to medical management with high risk of death, early liver transplantation for highly selected patients should be considered according to regional and institutional protocols (conditional recommendation, low level of evidence); LT selection must not be based solely on an arbitrary duration of sobriety, and should rest on detailed psychosocial evaluation by a social worker and addiction specialist, optionally supported by tools such as SIPAT, HRAR, MAPS, HPSS or SALT. For severe AH with 4 or more organ failures, non-responsive to corticosteroids and ineligible for early LT, palliative care engagement is appropriate.

American College of Gastroenterology (ACG), "ACG Clinical Guideline: Alcohol-Associated Liver Disease" (Jophlin, Singal, Bataller, et al.), Am J Gastroenterol 2024;119(1):30-54 · reviewed 2026-07-20 ↗
Gallaher C … Parker R · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Hepatology prospective cohort · n=34,756 · Nov 1, 2026 · Liver International · IF 6.7

The Association Between Alcohol Intake and Incident Major Adverse Liver Outcomes Remains Stable Despite Rising Metabolic Risk.

New evidencealcohol-associated liver diseaseepidemiologyMASLD
Clinical takeawayContinue to counsel patients on alcohol reduction as a key strategy to prevent liver disease, regardless of metabolic risk factors.
What it foundAlcohol intake remained associated with major adverse liver outcomes (HR 1.28 in 1992, HR 1.33 in 2012) despite rising metabolic risk factors.
ContextConfirms that alcohol remains a stable risk factor for liver outcomes, even as metabolic risk factors like obesity and diabetes have increased.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Katunin E … Åberg F · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink

Pancreas/Biliary· 1

Pancreas/Biliary rct · n=146 · Oct 27, 2026 · Hepatology · IF 18.0

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

New evidencecholangiocarcinomabiomarker
Clinical takeawayOpen-label and non-controlled: activity was concentrated in FGFR2 fusions and modest with mutations or amplifications, and derazantinib was not compared with any other therapy.
What it foundWith FGFR2 fusions (n=103), objective response was 22.3%, median PFS 8.1 months and OS 17.2 months; with FGFR2 mutations or amplifications, response was 9.3%, 3-month PFS 63% and OS 11.9 months. Hyperphosphataemia occurred in 38% and dry eye in 36%, with no grade 4 or 5 drug-related events.
ContextPhase 2 evidence with central radiology review in advanced intrahepatic cholangiocarcinoma after at least one line of chemotherapy.
Emergingsuggested applicable standard· NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma

Decision at stakeidentifying actionable targets for later-line therapy in unresectable/metastatic cholangiocarcinoma

… For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Stage cholangiocarcinoma with multiphasic MRI/MRCP plus CT chest/abdomen/pelvis, obtain tissue via ERCP brush cytology with FISH, cholangioscopy-directed biopsy, or EUS-FNA (avoiding primary perihilar tumor sampling if liver transplant is being considered due to theoretical seeding risk), and manage through a multidisciplinary tumor board with treatment stratified by tumor location: resect (anatomic hepatectomy for intrahepatic, hemihepatectomy with bile duct resection for perihilar, Whipple for distal) with adjuvant capecitabine (category 1, per BILCAP) when resectable. For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. Selected unresectable early-stage perihilar tumors may undergo neoadjuvant chemoradiation and liver transplant per the Mayo Clinic protocol at experienced centers, and jaundice or cholangitis is managed with biliary drainage (ERCP preferred over PTC).

NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma · reviewed 2026-07-21 ↗
Borad MJ … Mazzaferro V · Hepatology · IF 18.0 · PubMed ↗Permalink

Endoscopy· 3

Endoscopy prospective cohort · n=1,023 · Oct 30, 2026 · GIE · IF 8.0

Prospective multicenter evaluation of aceto-electronic chromoendoscopy added to Narrow-Band Imaging for real-time identification of deep submucosal invasion in colorectal polyps.

New evidencecolonoscopypolypectomycomputer-aided detectioncolorectal cancer
Clinical takeawayConsider using AEC in addition to M-NBI for real-time optical diagnosis of deep submucosal invasion in colorectal polyps ≥10 mm, particularly when deep invasion is suspected.
What it foundAdding aceto-electronic chromoendoscopy (AEC) to magnifying narrow-band imaging (M-NBI) improved specificity for deep submucosal invasion from 56.9% to 74.5% and overall accuracy from 60.3% to 77.6% (P < .0001).
ContextThis study refines current practice by demonstrating that AEC enhances the diagnostic accuracy of M-NBI, reducing overdiagnosis and improving specificity in identifying T1b lesions.
Measured against the standard of care· USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. Management starts with a careful endoscopic assessment for features of deep submucosal invasion (for example, NICE type 3 or excavated morphology). … A nonpedunculated lesion at high risk of superficial submucosal invasion should be removed en bloc, with proper specimen handling. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For colorectal lesions suspected to contain early (T1) cancer, US practice follows the USMSTF 2020 guideline on malignant colorectal polyps, with the AGA 2025 Clinical Practice Update commentary added on top. Management starts with a careful endoscopic assessment for features of deep submucosal invasion (for example, NICE type 3 or excavated morphology). A nonpedunculated lesion with deep-invasion features should be biopsied and tattooed, then referred for surgical resection. The AGA 2025 commentary adds that endoscopic local excision, including endoscopic full-thickness resection for selected T1 lesions under 2 cm, can be considered where technically feasible. A nonpedunculated lesion at high risk of superficial submucosal invasion should be removed en bloc, with proper specimen handling. ESD is often preferred to EMR because it achieves higher en bloc rates. Piecemeal resection of a suspected cancer is discouraged: it compromises histologic staging and independently predicts recurrence, and NCCN treats a T1 cancer removed piecemeal as needing surgery. After complete endoscopic removal of a malignant polyp, whether to recommend surgery depends on polyp shape, whether en bloc resection and an adequate histologic assessment were achieved, unfavorable histologic features (lymph node metastasis risk), surgical risk, and patient preference. The AGA 2025 commentary advises referral to a high-volume center with endoscopic resection and pathology expertise when the diagnosis is unclear and suspicion for cancer is high. It also advises expert GI pathology review and multidisciplinary discussion of resected T1 specimens. Lesions resected en bloc with no unfavorable histology can be managed with endoscopic surveillance instead of surgery.

USMSTF 2020 (Shaukat et al.) / AGA Clinical Practice Update Commentary 2025 (Ngamruengphong et al.), created from: AGA Clinical Practice Update on Endoscopic Resection for Early Colorectal Cancer: Commentary (2025), https://doi.org/10.1053/j.gastro.2025.09.001 · reviewed 2026-10-11 ↗
Yamamoto S … Kodama T · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
Endoscopy rct · n=248 · Oct 26, 2026 · J Clin Gastro · IF 2.9

Distributed Sample Allocation for the Diagnosis of Mass Lesions by EUS-FNA: A Prospective, Multicenter, Randomized Controlled Study.

New evidenceEUSendoscopy qualitycomputer-aided detection
Clinical takeawayConsider using distributed sample allocation during EUS-FNA procedures to improve diagnostic accuracy, particularly for mediastinal/lung lesions and cystic solid lesions. Ensure proper training and protocol adherence for optimal implementation.
What it foundDistributed sample allocation raised EUS-FNA diagnostic accuracy from 88.31% to 96.34% (P=0.0262), with notable improvement in mediastinal/lung lesions (P=0.0128) and cystic solid lesions (P=0.0235).
ContextThis study introduces a novel approach to EUS-FNA sample handling, refining current practice by optimizing diagnostic accuracy through distributed sample allocation. The findings are particularly relevant for patients with mediastinal/lung lesions and cystic solid lesions.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Han C … Lin R · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
Endoscopy rct · n=60 · Oct 29, 2026 · Dig Liver Dis · IF 4.2

Comparing precutting endoscopic band ligation-assisted resection vs ESD for small gastric SMTs: a randomized controlled trial.

New evidenceESDEMRcost-effectivenessendoscopy quality
Clinical takeawayPrecutting EBLR may be considered as a faster and cost-effective alternative to ESD for small gastric SMTs ≤ 16 mm, particularly in non-academic or lower-volume centers, pending further validation.
What it foundPrecutting EBLR reduced median operation time to 17.5 min compared to 30 min for ESD in gSMT-MP ≤ 16 mm.
ContextOffers a potential alternative to ESD for small gastric SMTs ≤ 16 mm, with shorter operation times and lower costs, though further validation is needed.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Zhou Y … Deng L · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink

Motility· 1

Motility meta analysis · Oct 26, 2026 · BMC Gastro · IF 2.5

Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation - a systematic review and meta-analysis with GRADE assessment.

New evidencechronic constipationIBSmeta-analysissystematic review
Clinical takeawayConsider plecanatide, particularly the 3 mg dose, for adults with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C), balancing efficacy and safety, while monitoring for diarrhea, the most frequent adverse event.
What it foundPlecanatide significantly increased complete spontaneous bowel movements (CSBMs) by 0.75-1.00 across doses compared to placebo, with the greatest improvement at 9 mg, and improved spontaneous bowel movements (SBMs) by 0.97-1.58 at 1-6 mg.
ContextConfirms plecanatide's efficacy and safety in adults with CIC and IBS-C, refining dose selection with evidence supporting 3 mg as optimal, though diarrhea remains a dose-related concern.
Measured against the standard of care· AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993)

First-line drug treatment for adults with chronic idiopathic constipation has not changed. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

First-line drug treatment for adults with chronic idiopathic constipation has not changed. It still follows the AGA-ACG 2023 GRADE guideline. STRONG recommendation (moderate certainty) for polyethylene glycol. STRONG recommendation (moderate certainty) for bisacodyl or sodium picosulfate, limited to short-term or rescue use. CONDITIONAL suggestion for fiber (low certainty), magnesium oxide (very low) and senna (low). For patients who do not respond to, fail, or cannot tolerate over-the-counter agents: STRONG recommendation (moderate certainty) for linaclotide, plecanatide and prucalopride, and CONDITIONAL suggestion for lubiprostone (low) and lactulose (very low). The guideline gives no doses, no required order and no fixed trial length; it uses shared decision making and leaves anorectal evacuation disorders to the ACG 2021 benign anorectal guideline. Added on top of this is the AGA 2026 Clinical Practice Update on refractory constipation (Staller, Neshatian, Lembo, Bharucha; expert-opinion Best Practice Advice, 14 key clinical issues, no formal evidence grading). Before calling constipation refractory, clinicians should systematically (1) exclude correctable secondary causes: medications, neurologic disorders, and defecatory disorders; (2) confirm slow colonic transit objectively, ideally both off therapy and on maximal therapy; and (3) make sure the patient has had adequate trials of over-the-counter and FDA-approved drugs and nonpharmacologic therapy, including combinations. Most patients should have anorectal testing and, when indicated, pelvic floor biofeedback before being labeled refractory. Colectomy can be considered only after all of these fail. Before surgery: confirm slow transit, exclude a concurrent defecatory disorder, evaluate for severe symptomatic delayed gastric emptying or small-bowel dysmotility, and do a psychological evaluation. Relative contraindications are clinically significant upper-gut dysmotility, severe untreated psychiatric disease, and bloating or abdominal pain as the main complaint. A temporary diverting loop ileostomy may predict response in uncertain cases. Colectomy with ileorectal anastomosis should be offered only to patients without an ongoing defecatory disorder. For obstructed defecation and posterior compartment or rectal prolapse, a 2026 consensus of the ASCRS Pelvic Floor Consortium with ICS, IUGA, AUGS and APTA (15 statements, >70% consensus, expert-consensus evidence) advises prompt referral to pelvic floor physical therapy for patients without contraindications. It also advises therapy individualized to the diagnostic evaluation and the patient's goals, deliberate timing of therapy relative to surgery, and trauma-informed care.

AGA-ACG 2023 (Chang L et al., Am J Gastroenterol 2023;118:936-954, doi 10.14309/ajg.0000000000002227) / AGA Clinical Practice Update 2026 (Staller K et al., Clin Gastroenterol Hepatol 2026;24(2):296-305, doi 10.1016/j.cgh.2025.09.031, PMID 41504675) / ASCRS-ICS-IUGA-AUGS-APTA Pelvic Floor Consortium consensus 2026 (Traugott AL et al., Dis Colon Rectum 2026;69(3):346-359, doi 10.1097/DCR.0000000000003993) · reviewed 2026-10-25 ↗
Aboelkhier MM … Alsayed AR · BMC Gastroenterology · IF 2.5 · PubMed ↗Permalink

Colorectal· 1

Colorectal review · Oct 28, 2026 · Am J Gastro · IF 9.8

Preventing Clostridioides difficile Infection and Recurrence: Practical Strategies for Clinical Practice.

Guideline / reviewmicrobiomesystematic reviewguideline
Clinical takeawayConsider extended antibiotic regimens, oral vancomycin prophylaxis during subsequent systemic antibiotic exposure, and microbiome restoration therapies for patients with CDI, especially those at high risk of recurrence (older adults, immunocompromised individuals, transplant recipients, and patients with IBD), while monitoring for potential adverse events.
What it foundExtended antibiotic regimens, oral vancomycin prophylaxis during systemic antibiotic exposure, and microbiome restoration therapies (e.g., fecal microbiota transplantation or FDA-approved microbiota-based therapies) reduce recurrent Clostridioides difficile infection (rCDI) compared to standard care.
ContextThis review confirms and refines current strategies for preventing CDI and rCDI, emphasizing microbiome preservation and restoration as central to reducing recurrence.
Measured against the standard of care· AGA Clinical Practice Update (Expert Review) on CDI in Adults, Clin Gastroenterol Hepatol 2026 / AGA Clinical Practice Update on CDI in IBD, Gastroenterology 2026 / ACG 2021 (superseded where they conflict)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Two 2026 AGA expert reviews now take precedence over the ACG 2021 guideline on several points. They are the AGA Clinical Practice Update on CDI in adults (Clin Gastroenterol Hepatol 2026; 14 best practice advice statements) and the AGA update on CDI in IBD (Gastroenterology 2026; 12 statements). Neither grades its statements with GRADE. DIAGNOSIS: CDI is a clinical diagnosis that needs compatible symptoms (about 3 or more unformed stools in 24 h) plus supportive lab testing. A multistep algorithm is preferred: a sensitive test (GDH or NAAT), then toxin EIA. A NAAT+/EIA- result should be read with caution, and patients with discordant results but high clinical suspicion should still be treated. SEVERITY: classify hospitalized patients at diagnosis. Severe is WBC >15,000/µL and/or creatinine >1.5 (ACG: >1.5 mg/dL; one secondary summary of the AGA text reports >1.5 times baseline). Fulminant is shock, ileus, or megacolon. INITIAL NONFULMINANT EPISODE (nonsevere or severe): fidaxomicin 200 mg twice daily for 10 days is favored first-line because of its narrower spectrum and lower recurrence. Oral vancomycin 125 mg four times daily for 10 days is an acceptable alternative. Metronidazole should not be used outside fulminant disease, which removes the ACG 2021 low-risk metronidazole option. Do not use cholestyramine or other bile-acid binders as monotherapy or alongside vancomycin or fidaxomicin. FULMINANT: manage with a multidisciplinary team. Give oral or enteral vancomycin 500 mg every 6 hours plus IV metronidazole 500 mg every 8 hours, and add rectal vancomycin 500 mg every 6 hours if ileus is present. Consider multi-dose FMT by lower endoscopy. The licensed products (fecal microbiota, live-jslm; fecal microbiota spores, live-brpk) are not approved for severe or fulminant CDI. After severe or fulminant CDI, keep the patient on suppressive vancomycin until a final outpatient FMT. FIRST RECURRENCE (within 8 weeks of finishing therapy): tapering/pulsed vancomycin or fidaxomicin, plus a recurrence-risk assessment and consideration of microbiota restoration. MICROBIOTA-BASED THERAPY (FMT or the licensed products): offer after treatment of a second recurrence. Consider it after an initial episode or first recurrence in patients at high risk of further recurrence or with a severe or refractory episode. SUPPRESSION: consider prolonged low-dose vancomycin 125 mg daily for patients with multiple recurrences who cannot receive or have failed microbiota-based therapy, have limited life expectancy or ongoing comorbidities, or need frequent systemic antibiotics. PREVENTION: do not use vancomycin prophylaxis during systemic antibiotics in the general population. Do not use probiotics for primary or secondary prevention. Encourage a high-fiber diet. Do not stop a PPI that has a legitimate indication, but review its use. Counsel patients with prior CDI to avoid unnecessary antibiotics. Use barrier precautions and EPA-approved sporicidal disinfection. No routine test of cure: retest only for persistent or worsening diarrhea. Bezlotoxumab does not appear in the AGA statements (Merck discontinued it in January 2025). IBD (AGA 2026): test for CDI in IBD patients with new or worsening diarrhea, including those with a pouch or ileostomy, using a multistep toxin-based assay. Treat a first episode preferentially with fidaxomicin, or vancomycin if fidaxomicin is unavailable or too costly. Never use metronidazole. Continue necessary IBD immunosuppression during CDI, and steroids may be used if needed. If symptoms persist after 48-72 h of treatment, consider endoscopy to assess IBD activity and CMV. Offer microbiome-based therapy after at least one recurrence. No probiotics. Oral vancomycin prophylaxis may be considered during systemic antibiotics in IBD patients with prior CDI. The summaries reviewed did not mention the ACG 14-day minimum vancomycin course in IBD.

AGA Clinical Practice Update (Expert Review) on CDI in Adults, Clin Gastroenterol Hepatol 2026 / AGA Clinical Practice Update on CDI in IBD, Gastroenterology 2026 / ACG 2021 (superseded where they conflict) · reviewed 2026-10-11 ↗
Axelrad JE, Allegretti JR · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Everything else this week64 that cleared the bar

Ranked below the cards above, not excluded: these met the bar and were read and scored the same way. One line each, grouped by subspecialty, highest signal first; click through for the paper.

IBD· 14

Hepatology· 23

Also screened this week78 papers read, not selected

These cleared the journal filter and were read, but were not selected this week. A score means the paper was weighed: below 35 it fell short of the bar; at 35 or above, a check after scoring set it aside. A blank means it was set aside before scoring. Listed for anyone going deeper; no takeaway attached, because none was written. How we choose →

Hepatology· 21

Endoscopy· 26

How we choose

the same pipeline every week
01

Scan

Every new paper across 48 vetted GI, hepatology, and general-medicine journals.

02

Screen

Drop what is not a study: letters, editorials, corrections, case reports. Classify the rest.

03

Anchor

Compare each paper to the guideline standard it touches, and record how far it moves it.

04

Verify

An adversarial second pass checks every claim against its cited source.

05

Vet

Each issue is reviewed by a physician editor before it publishes.